⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6265509 | 0.79 | FFAR1 (0.32) | — | |
| SCHEMBL6919173 | 0.77 | ALDH1A1 (0.47) | — | |
| SCHEMBL28879879 | 0.77 | LOXL2 (0.52) | — | |
| SCHEMBL8040944 | 0.74 | CA1 (0.35) | — | |
| SCHEMBL104811 | 0.71 | APP (0.32) | — | |
| SCHEMBL11153987 | 0.70 | KDM4E (0.43) | — | |
| SCHEMBL23091413 | 0.69 | IDO1 (0.46) | — | |
| SCHEMBL10402221 | 0.69 | ESR1 (0.50) | — | |
| SCHEMBL4921070 | 0.69 | HRH3 (0.32) | — | |
| SCHEMBL1802180 | 0.69 | CA1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326350-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | Psma Development Company, L.L.C. (US) | 2011-06-01 | — | — | EP | claimed |
| WO-2010027513-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEVELOPMENT COMPANY, LLC (US) | 2010-03-11 | — | — | WO | claimed |
| EP-1718667-A4 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH INC (US) | 2009-04-08 | — | — | EP | claimed |
| EP-1912677-A2 | PSMA ANTIBODY-DRUG CONJUGATES | Psma Development Company, L.L.C. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | claimed |
| EP-1718667-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082023-A2 | HETEROCYCLIC SELF-IMMOLATIVE LINKERS AND CONJUGATES | GENENTECH, INC. (US) | 2005-09-09 | — | — | WO | claimed |
| EP-3057614-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | Psma Development Company, L.L.C. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015057250-A1 | COMBINATION THERAPIES WITH PSMA LIGAND CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-2326350-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | Psma Development Company, L.L.C. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010027513-A2 | METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS | PSMA DEVELOPMENT COMPANY, LLC (US) | 2010-03-11 | — | — | WO | disclosed |
| EP-1912677-A2 | PSMA ANTIBODY-DRUG CONJUGATES | Psma Development Company, L.L.C. (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007002222-A2 | PSMA ANTIBODY-DRUG CONJUGATES | PSMA DEVELOPMENT COMPANY, LLC (US) | 2007-01-04 | — | — | WO | disclosed |